Cryoport Wins 2016 Cold Chain Global Forum Excellence Award

Recognized for "Most Effective Risk Assessment, Evaluation and Mitigation for Transportation"

IRVINE, Calif., Oct. 4, 2016 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Company"), the world's leading cryogenic logistics company dedicated to the life sciences, announced today that the Company has won the 2016 Cold Chain Global Forum Excellence Award. The Awards program is the largest and most recognized annual industry event, honoring and celebrating the innovators and thought leading professionals and organizations which have substantially exceeded industry standards. The awards are to highlight the very best of these projects, and give international, industry-wide recognition to those who have earned them.

Cryoport, Inc.

The award was accepted on September 29th, on behalf of Cryoport, by Dr. Robert Moore, in the category of "Most Effective Risk Assessment, Evaluation and Mitigation for Transportation" for the Company's work with a global animal health company which produces quality vaccines, parasiticides, anti-infectives, medicinal feed additives and other pharmaceuticals, along with diagnostic products and genetic tests. The winning project was Cryoport's selection and successful implementation of a complete, outsourced, turnkey management solution for a client's fleet of cryogenic shipping and storage requirements for animal vaccines, which resulted in the client realizing an approximate $1.6 million reduction in annual costs.

"We are pleased to receive this award. It is a further validation of Cryoport's ability to deliver unmatched cold chain logistics solutions for the life sciences," said Jerrell Shelton, Chief Executive Officer of Cryoport, Inc. "Cryoport is the only temperature controlled provider to the life sciences capable of delivering comprehensive outsourced solutions for cold chain logistics fleet management and vital information needs. Cryoport's tools and technology allow our staff to record real time information about complete conditions of commodities as well as location and status of shippers. We mitigate risks in all aspects of the logistics process through our advanced technologies and know how."

About Cryoport, Inc.
Cryoport is the life sciences industry's most trusted global provider of cold chain logistics solutions for temperature-sensitive life sciences commodities, serving the biopharmaceutical market with leading-edge logistics solutions for biologic materials, such as immunotherapies, stem cells and CAR-T cells. Cryoport's solutions are used by points-of-care, CRO's, central laboratories, pharmaceutical companies, manufacturers, university researchers et al; as well as the reproductive medicine market, primarily in IVF and surrogacy; and the animal health market, primarily in the areas of vaccines and reproductive medicine. Cryoport's proprietary Cryoport Express® Shippers, Cryoportal™ Logistics Management Platform, leading-edge SmartPak II™ Condition Monitoring System and geo-sensing technology, paired with unparalleled cold chain logistics expertise and 24/7 client support, make Cryoport the end-to-end cold chain logistics partner that the industry trusts.

Cryoport is dedicated to

  • simplifying global cold chain logistics through innovative technology, unmatched monitoring and data capture and support, including consulting;
  • delivering the most advanced temperature controlled logistics solutions for the life sciences industry; and
  • providing vital information that provides peace of mind throughout the life of each logistics process

For more information, visit To download Cryoport's investor relations app, which offers access to SEC documents, press releases, videos, audiocasts and more, please click to download from your iPhone and iPad or Android mobile device.

Forward Looking Statements
Statements in this news release which are not purely historical, including statements regarding Cryoport, Inc.'s intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic conditions, trends in the products markets, variations in the company's cash flow, market acceptance risks, and technical development risks. The company's business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended March 31, 2016. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Cryoport, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

Logo -


To view the original version on PR Newswire, visit:

SOURCE Cryoport, Inc.